DxTerity Diagnostics is at the forefront of precision medicine, particularly in the realm of autoimmune diseases, utilizing innovative RNA diagnostics to enhance patient care. The company has developed a unique Modular Immune Profile (MIP) test that measures the expression of immune system-related genes, providing insights into the biological mechanisms underlying conditions such as Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), and Rheumatoid Arthritis (RA). This RNA-based approach differs significantly from traditional DNA testing, as RNA reflects real-time changes in a patient's health and environmental interactions, offering a more dynamic understanding of disease status. The MIP test is designed for high-throughput processing and eliminates the need for sample purification, making it both efficient and cost-effective.

In addition to its diagnostic capabilities, DxTerity emphasizes patient empowerment through convenient at-home sample collection methods. Their patented micro-collection device (MCD) stabilizes RNA samples for extended periods, facilitating easy shipping and handling. The company is also committed to advancing clinical research by partnering with pharmaceutical and academic institutions to conduct studies that enhance the understanding and treatment of autoimmune diseases. Through initiatives like the ELEVATE and LIFT clinical studies, DxTerity aims to gather real-world evidence that underscores the value of RNA testing, ultimately striving to improve patient outcomes and quality of life.

United States

DxTerity is bringing the power of precision medicine to autoimmune disease.

We are pioneering the use of RNA-based immune system profiling to better understand the root causes of immune mediated conditions. Our goal is to provide more personalized care for autoimmune sufferers and empower patients with more detailed information about their condition so they can better navigate their complex health journey.

DxTerity Diagnostics

Company Details